METHYLENE BLUE 10mg 60 caps

Methylene Blue functions simultaneously as a registered medicinal product (Provayblue®/Proveblue® — methylthioninium chloride for intravenous administration, indication: methemoglobinemia, antidote) and as a reagent and preparation outside the dietary supplement framework. This Pro-Body preparation is the

equivalent of the same molecule in pharmaceutical quality (USP grade), in 10 mg capsules — it is not a medicinal product, it is not a substitute for Provayblue®, and it does not serve to treat methemoglobinemia or any other condition.

WARNING — RISK OF SEROTONIN SYNDROME

Methylene blue is a monoamine oxidase inhibitor (MAO-A and MAO-B). Combining it with serotonergic drugs — SSRIs, SNRIs, tricyclic antidepressants, MAOIs, tramadol, fentanyl, pethidine, dextromethorphan, triptans, bupropion, St. John’s wort preparations — may trigger serotonin syndrome: a life-threatening condition (fever, muscle rigidity, seizures, altered consciousness, circulatory failure). In 2011 the FDA issued a Drug Safety Communication warning about this interaction. If you are taking any of the listed drugs — do not reach for this preparation.

Methylene blue has 130 years of medical history behind it. Paul Ehrlich stained neurons with it in 1886, in 1891 it became the first fully synthetic drug administered to a human (against malaria), and today — under the names Provayblue® and Proveblue® — it remains a registered intravenous drug for methemoglobinemia. Over the last two decades the same molecule has come under the microscope of neuropharmacology for an entirely different reason: in low doses it behaves like an alternative electron carrier in the mitochondrial respiratory chain, bypassing damaged complexes I and III and restoring ATP production where energy metabolism falters.

It is precisely this profile that has made methylene blue one of the most recognizable compounds in the biohacker community. The mitochondrion — the cell’s energy factory — is where almost all of the organism’s ATP is produced, and its efficiency declines with age, oxidative stress and metabolic overload. The logic of the interest is simple: a molecule that can support electron flow through the respiratory chain touches the very core of energy metabolism.

Coach Marek would put it bluntly: if any compound deserves the label “mitochondrial,” it is this one — but the very same redox activity that makes it interesting also makes it a compound with a narrow window and one truly dangerous interaction.

This preparation consists of 10 mg capsules of methylene blue in pharmaceutical quality (USP grade), purity ≥98% HPLC, identity confirmed by mass spectrometry, COA available for every batch. The capsule format delivers what a solution does not: a fixed, repeatable, low-dose portion without the need to measure out drops and without staining the oral cavity.

Each capsule is exactly 10 mg — a dose that falls within the lower part of methylene blue’s “hormetic window,” where the pro-mitochondrial profile dominates. This is convenience and repeatability in exchange for the titration precision offered by the liquid 30 mg/ml variant for titration.

To understand why low-dose methylene blue arouses metabolic interest, one must look at the mitochondrial respiratory chain. It is a sequence of four protein complexes in the inner mitochondrial membrane, through which electrons derived from the breakdown of food are gradually passed all the way to oxygen — and the energy released along the way drives the synthesis of ATP, the cell’s universal “energy currency.”

The critical points of this sequence are complex I (NADH oxidoreductase) and complex III. These are the ones most often damaged under conditions of oxidative stress, hypoxia or neurodegeneration — and their dysfunction means a bottleneck for the entire electron flow and a drop in ATP production. The final link in the chain is complex IV (cytochrome c oxidase) — the enzyme that passes electrons directly to oxygen.

Methylene blue enters this system as a redox-active molecule capable of reversibly accepting and donating electrons. In practice it acts like a makeshift “detour”: it accepts electrons early and passes them on further, bypassing the clogged complexes I and III, while at the same time supporting the activity of complex IV. Hence the reputation of an “electron carrier” and the reason the compound draws attention wherever the problem is an energy deficit of the nerve cell.

Chemically, methylene blue is a phenothiazine thiazine dye — a heterocyclic aromatic compound with an intensely blue color in its oxidized form.

• Common name: methylene blue, Methylene Blue (MB)
• Chemical name: methylthioninium chloride
• CAS number: 61-73-4
• Molecular formula: C₁₆H₁₈ClN₃S
• Molar mass: 319.85 g/mol (anhydrous form)
• Chemical class: phenothiazine thiazine dye (heterocyclic aromatic compound)
• Form supplied: 10 mg methylene blue capsules, pack of 60; pharmaceutical/USP grade
• Quality: purity ≥98% HPLC, identity confirmed by MS, heavy metal control in the COA
• Solubility: readily soluble in water (intensely blue solution)

Origin:

Methylene blue was synthesized by Heinrich Caro at BASF in 1876 as an industrial dye. As early as 1891 Paul Guttmann and Paul Ehrlich used it as the first synthetic antimalarial agent — which makes it historically the first fully synthetic drug in medicine. Today it is used intravenously in the treatment of methemoglobinemia (as the drug Provayblue®/Proveblue®) and as a diagnostic dye. Neuropharmacological interest in low oral doses developed mainly after 2000, in the context of mitochondrial dysfunction and neurodegeneration.

SCIENTIFIC PERSPECTIVE

The 10 mg capsule format was chosen for a fixed, repeatable, low dose — a value falling within the lower part of methylene blue’s “hormetic window,” where the profile supporting mitochondrial metabolism dominates. Most data on low-dose methylene blue in the context of cognitive function come from preclinical models (rodents, cell cultures) and individual, small human studies on memory and cerebral blood flow (Rodriguez et al. 2016).

There are no large, multicenter clinical trials confirming a “nootropic” profile of methylene blue in healthy adults. The optimism of the mechanistic data should be balanced with realism regarding the strength of the clinical evidence.

Methylene blue has no single receptor. Its profile is the resultant of the redox-active chemistry of a molecule capable of reversibly accepting and donating electrons — and it is precisely this feature that underlies most of the observed effects.

Alternative electron carrier — bypass of complexes I and III

At the heart of methylene blue’s action is the alternating transition between its oxidized form (MB⁺, blue) and reduced form (leuco-MB, colorless). In the mitochondrion MB⁺ accepts electrons from NADH and from NADPH dehydrogenase, and then donates them directly to cytochrome c — bypassing complex I and complex III of the respiratory chain. In practice: when these complexes are damaged (by toxins, hypoxia, neurodegeneration), methylene blue acts like a makeshift “detour” for electrons, sustaining flow through the chain and ATP production (Oz et al. 2011; Tucker et al. 2018).

This is the mechanism that explains why the compound arouses interest wherever the problem is an energy deficit of the cell — and the direct supply to complex IV (cytochrome c oxidase) translates in models into an increase in oxygen consumption and ATP synthesis.

Hormetic dose dependence — the inverted-U-shaped curve

Here the central pharmacological feature of methylene blue appears: hormesis. At low concentrations (in rodent models on the order of 0.5–4 mg/kg) the molecule supports energy metabolism and acts as an antioxidant; above this threshold it begins to act pro-oxidatively and inhibits mitochondrial respiration. The dependence has the shape of an inverted U: the benefit grows with dose only up to a certain point, after which the effect reverses (Rojas et al. 2012; Oz et al. 2011).

This is the biochemical justification for the rule “little, not much” — escalation not only fails to help, but turns the compound’s profile against the mitochondrion. A fixed, low dose of 10 mg has structural significance in this context: it keeps the preparation in the ascending phase of the curve.

Reversible MAO inhibition — the source of the most dangerous interaction

At higher doses methylene blue inhibits monoamine oxidase — the enzyme that breaks down serotonin, noradrenaline and dopamine. Ramsay et al. (2007) demonstrated that it is a potent MAO-A inhibitor with an affinity close to that of classical MAOIs, which makes the interaction with serotonergic drugs a real, not theoretical, threat. The mechanism is simple and brutal: if MAO is blocked while a serotonergic drug simultaneously increases the concentration of serotonin in the synapse, serotonin has no way to be broken down — and accumulates to a toxic level.

This is the biochemical basis of serotonin syndrome and the reason the FDA in 2011 warned against combining methylthioninium with serotonergic drugs.

Neuroprotection in models — tau aggregation, memory, cerebral blood flow

In vitro, methylene blue inhibits the aggregation of tau protein and β-amyloid — two markers of neuropathology. It is precisely this direction that led to the development of the derivative LMTM / hydromethylthionine (leuco-methylthioninium), which advanced to clinical trials in Alzheimer’s disease (the TauRx line; Gauthier et al. 2016). It is worth being precise: it was the derivative, not methylene blue itself in chloride form, that was the subject of large clinical trials, and the results of those trials remain a matter of methodological debate.

Regardless of this, in preclinical models of Parkinson’s and Alzheimer’s, methylene blue itself showed neuroprotective action — it limited neuron loss and markers of oxidative stress and improved memory parameters in rodents (Tucker et al. 2018). In humans, a single imaging study (Rodriguez et al. 2016, multimodal fMRI) reported an effect of a low dose on the activity of areas associated with working memory and consolidation.

With its neurotrophic and neuroprotective profile, methylene blue fits into the broader shelf of compounds studied for cognitive function — mechanistically distinct, but considered in a similar context, such as DIHEXA with its synaptogenic profile (the HGF/c-Met axis) or 9-MBC as a dopaminergic neuroprotectant from preclinical studies of Parkinson’s disease.

Two parameters determine whether low-dose methylene blue behaves like a metabolic tool or like a risk: dose and purity.

The hormetic window was described above — it is the narrow range in which the molecule’s profile is pro-mitochondrial, before escalation turns it toward the pro-oxidative. The 10 mg per capsule format is structurally positioned in the lower part of this window. Hormesis is a pharmacological concept, not a quantitative recommendation: it describes the shape of the biological response (the more, the better only up to the turning point), not a dosing regimen in humans, which this description does not provide.

USP purity vs technical grade is the second, equally important point — and here the pharmaceutical format has an advantage of a safety character, not merely marketing. Technical (dye-grade) methylene blue, used in industry and laboratories as a dye, may be contaminated with heavy metals (including arsenic, lead, cadmium, zinc, mercury) as well as related thiazine compounds and synthesis byproducts.

The difference between dye grade and pharmaceutical grade (USP) is not cosmetic: it is the presence or absence of contaminants that no one wants to introduce into the body. A USP-grade preparation undergoes control of the impurity profile — including determination of heavy metals, reported in the batch COA. It is precisely this control that distinguishes a pharmaceutical preparation from dye-grade methylene blue, which — regardless of price and color — cannot be considered suitable for any contact with the body.

Methylene blue has a real risk profile and a narrow therapeutic window. Two hazards are critical in nature and are non-negotiable.

WARNING — TWO ABSOLUTE CONTRAINDICATIONS

(1) Serotonergic drugs and serotonin syndrome. Methylene blue inhibits MAO. In combination with SSRIs, SNRIs, MAOIs, tricyclic antidepressants, tramadol, fentanyl, pethidine, dextromethorphan, triptans, bupropion or St. John’s wort, it may trigger a potentially fatal serotonin syndrome. The absolute prohibition on combination applies throughout the half-life of these drugs (for some SSRIs this is weeks after discontinuation).

(2) G6PD deficiency and the risk of hemolysis. In people with glucose-6-phosphate dehydrogenase (G6PD) deficiency — a congenital enzymopathy affecting hundreds of millions of people — methylene blue may trigger acute hemolysis (breakdown of red blood cells). G6PD deficiency is an absolute contraindication. If you do not know whether you have it, that means you should not reach for this compound without prior diagnostic testing.

Other principles

• Do not combine with other MAO inhibitors or with serotonergic substances (including some nootropics and plant extracts)
• Do not escalate the dose — the hormetic curve reverses the benefit beyond the narrow window
• Renal failure and severe hepatic failure are contraindications (elimination and metabolism of the molecule)
• Green-blue discoloration of urine (sometimes saliva) is normal and harmless — it results from excretion of the dye and resolves after discontinuation of use
• Cyclical use, not continuous — the long half-life (10–18 h) means accumulation of the compound

Absolute contraindications

• Pregnancy and breastfeeding
• Age under 21
• G6PD deficiency (risk of hemolysis)
• Current use of SSRIs, SNRIs, MAOIs, tricyclic antidepressants, tramadol, fentanyl, pethidine, dextromethorphan, triptans, bupropion, St. John’s wort (risk of fatal serotonin syndrome)
• Renal failure; severe hepatic failure

Low-dose methylene blue remains a subject of interest in several areas related to energy metabolism and central nervous system function. In preclinical models its effect on complex IV activity, ATP synthesis, oxidative stress markers and memory parameters is studied; in individual human studies — the effect of a low dose on cerebral blood flow and the activity of memory areas (Rodriguez et al. 2016). The compound is sometimes paired with other compounds from the brain function and cognitive function shelf as a tool for research into the energy metabolism of the neuron.

Specific research and exploratory directions include:

• Mitochondrial energetics — the role of methylene blue as an alternative electron carrier under conditions of complex I/III dysfunction; measurements of oxygen consumption and ATP synthesis
• Neuroprotection in models — rodent models of Parkinson’s and Alzheimer’s, markers of tau and β-amyloid aggregation, neuron survival parameters
• Cognitive function and imaging — the effect of a low dose on working memory and cerebral blood flow in fMRI studies (Rodriguez et al. 2016)
• Redox chemistry and hormesis — characterization of the inverted-U-shaped response curve and the threshold of profile transition from anti- to pro-oxidative

Methylene blue (methylthioninium chloride, CAS 61-73-4) is a phenothiazine thiazine dye with a unique redox profile: in low doses it acts as an alternative electron carrier in the mitochondrial respiratory chain, bypassing damaged complexes I and III and directly powering complex IV — which translates into support for ATP production and antioxidant protection in models of neurodegeneration (Oz et al. 2011; Tucker et al. 2018).

The profile, however, has two limitations of critical importance: the hormetic curve (above the narrow window the effect reverses pro-oxidatively) and MAO inhibition, which makes it dangerous in combination with serotonergic drugs (Ramsay et al. 2007). The derivative LMTM/hydromethylthionine advanced to clinical trials in Alzheimer’s disease (the TauRx line; Gauthier et al. 2016), and a single fMRI study reported the effect of a low dose on memory areas in humans (Rodriguez et al. 2016).

This preparation consists of 10 mg capsules in USP/pharmaceutical grade quality, purity ≥98% HPLC, MS confirmation, heavy metal control and COA per batch — a convenient, fixed, low-dose format for biohackers, a specialized nootropic-mitochondrial preparation for adults (21+), not a medicine and not a substitute for Provayblue®.

1. Rodriguez P, Zhou W, Barrett DW, Altmeyer W, Gutierrez JE, Li J, et al. (2016). Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain. PubMed
2. Tucker D, Lu Y, Zhang Q (2018). From Mitochondrial Function to Neuroprotection — an Emerging Role for Methylene Blue. PubMed
3. Oz M, Lorke DE, Hasan M, Petroianu GA (2011). Cellular and molecular actions of Methylene Blue in the nervous system. PubMed
4. Wen Y, Li W, Poteet EC, Xie L, Tan C, Yan LJ, et al. (2011). Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. PubMed
5. Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, et al. (2016). Efficacy and safety of tau-aggregation inhibitor therapy (LMTM) in mild to moderate Alzheimer’s disease: a randomised controlled trial. PubMed
6. Ramsay RR, Dunford C, Gillman PK (2007). Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. PubMed
7. Rojas JC, Bruchey AK, Gonzalez-Lima F (2012). Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. PubMed